New pharmaceutical products face many potential hurdles to commercial success including regulatory approval, national and regional market access, and physician and patient acceptance and uptake, to name a few. Each stage of the development cycle involves an ever-widening group of stakeholders. Securing the buy-in of these influential external stakeholders requires pharmaceutical companies to look inward and encourage cross-functional collaboration and the ability to engage early, and often, along the path to launch and beyond. To read more, click the link below.
Keytruda & PD-(L)1: Life after programmed death (Part 3)
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no...